RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Show more

Location: 21 Ha’arba’a Street, Tel Aviv, 6473921, Israel | Website: https://www.redhillbio.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

5.027M

52 Wk Range

$1.71 - $20.27

Previous Close

$2.13

Open

$2.14

Volume

11,504

Day Range

$2.11 - $2.19

Enterprise Value

25.02B

Cash

4.617M

Avg Qtr Burn

-2.342M

Insider Ownership

0.00%

Institutional Own.

5.67%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Movantik® (naloxegol) Details
Pain, Constipation, Biliary atresia, Liver disease

Approved

Quarterly sales

Approved

Quarterly sales

RHB-102 (Bekinda®) Details
Digestive tract, Stomach, Intestinal infection

Phase 3

Update

RHB-104 Details
Inflammatory disease, Crohns disease

Phase 3

Update

RHB-102 (Bekinda®) Details
Irritable bowel syndrome, Bowel disorder, Post-traumatic stress disorder, Psychiatric disorder

Phase 3

Initiation

Phase 2

Data readout

Opaganib + Darolutamide Details
Castration-resistant prostate cancer

Phase 2

Data readout

Opaganib Details
Obesity, Type 2 diabetes

Phase 1

Initiation

RHB-106 Details
Bowel preparation , Breast cancer

Failed

Discontinued

RHB-204 Details
Bacterial infection

Failed

Discontinued

Failed

Discontinued